Osteoporosis Trial, Recruiting (NCT06164795)

Osteoporosis Trial, Recruiting NCT06164795 Sponsor: 424 General Military Hospital Condition: Osteoporosis

Printed from Voxsanity (voxsanity.com.au) — NCT06164795 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Osteoporosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Women who have gone through menopause, have been diagnosed with severe osteoporosis, and have recently completed a full course of treatment with either romosozumab or teriparatide (two specific bone-strengthening medications)

Who may not be able to join:

People who have a bone condition other than osteoporosis caused by menopause
People who have taken medications that affect bone health (other than romosozumab or teriparatide) at any point in the 12 months before joining the study
People whose kidneys are not filtering blood well enough (confirm with trial site for exact measurement)
People with liver failure
People who have any type of cancer
People who have endocrine (hormone-related) diseases that are not well controlled
People whose vitamin D levels in the blood are too low (below a specific threshold — confirm with trial site)
People who have had an allergic reaction to any of the following medications: denosumab, zoledronate, teriparatide, romosozumab, or any of the inactive ingredients in those medications

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Willem Lems, Prof, ECTS Clinical Action Group

Phone: 2310381431

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06164795

Sponsor: 424 General Military Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Osteoporosis

Trial contact: 2310381431

More information: https://clinicaltrials.gov/study/NCT06164795

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Women who have gone through menopause, have been diagnosed with severe osteoporosis, and have recently completed a full course of treatment with either romosozumab or teriparatide (two specific bone-strengthening medications)

Who may not be able to join:

People who have a bone condition other than osteoporosis caused by menopause
People who have taken medications that affect bone health (other than romosozumab or teriparatide) at any point in the 12 months before joining the study
People whose kidneys are not filtering blood well enough (confirm with trial site for exact measurement)
People with liver failure
People who have any type of cancer
People who have endocrine (hormone-related) diseases that are not well controlled
People whose vitamin D levels in the blood are too low (below a specific threshold — confirm with trial site)
People who have had an allergic reaction to any of the following medications: denosumab, zoledronate, teriparatide, romosozumab, or any of the inactive ingredients in those medications

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

424 General Military Hospital

Registry

ClinicalTrials.gov

Start date

25 November 2023

Est. completion

1 June 2027

Where this trial is recruiting

🇬🇷 Greece 🇮🇹 Italy

Primary endpoints

lumbar spine bone mineral density

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov